Gilead rises after earnings beat driven by HIV drug sales
Gilead rose more than 5% on Wednesday after it reported quarterly earnings and revenue that beat Wall Street estimates, driven by sales of its HIV drugs.
For the last three months of 2025, Gilead reported:
Adjusted earnings per share of $1.86, compared to the $1.81 the Street was expecting.
$7.9 billion in revenue, more than the $7.6 billion the Street was penciling in. Late last year the company began selling Yeztugo, a twice-yearly HIV prevention shot. CEO Daniel O’Day told analysts it “has already exceeded our coverage goals and is rapidly gaining market share.”
For the full year in 2026, the company expects:
Adjusted earnings per share of $8.45 to $8.85, compared to the $8.79 analysts forecast.
Revenue of $29.6 billion to $30 billion, compared to the $29.92 billion the Street was expecting. The company anticipates Yeztugo will contribute $800 million in revenue in 2026.